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THE metabolic mechanism by which tryptophan is converted into nicotinic
acid appears to be altered in several human diseases. Yet it has not been possible
to demonstrate specific excretory patternsforthevarious diseases. The excretory
pattern in the urines of patients with cancer of the bladder is certainly the one
which presents the most specific and relevant alterations (Quagliariello, 1963).
Several authors have shown the presence of 3-hydroxyanthranilic acid in the
urine ofpatients with cancer ofthe bladder: Boyland and Williams using column
(1956a) and paper chromatography (1956b); Quagliariello, Auricchio, Casale and
Tancredi (1958) by means of paper chromatography; Tompsett (1959) and
Abul-Fadl and Khalafallah (1961) with a colorimetric method. Quagliariello,
Tancredi, Fedele and Saccone (1961) found that the amounts of 3-hydroxyanthra-
nilic acid, 3-hydroxynurenine and anthranilic acid excreted by bladder cancer
patients were reduced by giving large doses of nicotinamide. Allen, Boyland,
Dukes, Horning and Watson (1957) have shown that biological ortho-amino-
phenols, such as 3-hydroxyanthranilic acid and 3-hydroxykynurenine, can induce
experimental cancer of the bladder. Dunning, Curtis and Maun (1950) reported
that cancer of the urinary bladder, caused by 2-acetamido-fluorene, arose in
practically all cases in rats fed on a diet containing a high quantity oftryptophan.
Further, Quagliariello, Auricchio and Rinaldi (1958) found that on oral adminis-
tration of 2-acetamido-fluorene, 3-hydroxyanthranilic acid > quinolinic acid
conversion in rat liver was inhibited to a large extent. This metabolic block
would be expected to cause accumulation of carcinogenic substances such as
3-hydroxyanthranilic acid and 3-hydroxynurenine; this could give a tentative
explanation of the above reported findings of Dunning et al. Recently Ehrhart
and Georgii (1959) reported that 3-hydroxyanthranilic acid can induce myeloid
forms of leukaemia in mice (RFH-strain) with a low incidence of spontaneous
leukaemia. The leukaemia rate following the administration of 3-hydroxyanthra-
nilic acid could be increased by blocking 3-hydroxyanthranilic acid oxidase with
2-acetamido-fluorene (Ehrhart, 1962).
These studies prompted our further researches on the eventual connection
between tryptophan metabolism and carcinogenesis. In the present work the
excretion of 3-hydroxyanthranilic acid in the urine of patients with tumours of
the urinary bladder and of the kidney has been studied. None of the patients
with bladder cancer was engaged in the handling of aromatic amines.TRYPTOPHAN-NICOTINIC ACID METABOLISM
EXPERIMENTAL PROCEDURE
20 ml. of all the urines collected during the day were acidified with acetic
acid (1: 1) and centrifuged at low speed. Charcoal deactivated with 4 per cent
by weight of stearic acid was added to the supernatant and the mixture shaken
for 5-10 minutes. The charcoal was filtered off and washed with water to remove
the remaining salts, urea, sugars and aliphatic aminoacids. It was then eluted
with saturated aqueous phenol solution, previously heated at 400. The phenol
eluates were evaporated to dryness under vacuum at 50-600. The residues were
taken up in 0 5 ml. water; ofthis 0-2 ml. were spotted on Whatman No. 1 paper.
Two-dimensional descending runs were performed. The solvent for the first run
was the organic phase from a freshly prepared mixture of butanol: acetic acid:
water (4: 1:5; v/v).
Glass-bidistilled water was used for the second run. Tryptophan metabolites
were identified by fluorescence under ultraviolet light (3660 A) and by charac-
teristic colour reactions (ninhydrin reaction, Ehrlich's reagent, ammoniacal silver
nitrate; see Quagliariello et al., 1961). Reference standards of 3-hydroxyantha-
nilic acid and other tryptophan metabolites were run simultaneously.
Determination of 3-hydroxyanthranilic acid.-The pieces ofpaper corresponding
to the spots of 3-hydroxyanthranilic acid were cut out and eluted with 01 M
potassium-phosphate buffer pH 7-5. To 5 ml. of the eluate in test-tubes fitted
with ground-glass stoppers, were added: 4f5 ml. citrate-phosphate buffer pH 4.5,
0*5 ml. sodium carbonate (5 per cent), 2 ml. diazotized sulphanilic acid (0.5 per
cent in 2 per cent HC1, mixed, before using, with an equal volume of sodium
nitrite, 0 5 per cent in water; this last operation was carried out at 00). The
mixture was incubated for 30 minutes at 150. The 3-hydroxyanthranilic acid
concentration was calculated measuring the O.1D. at 450 m,t. The sensitivity
ranged between 1-50 ,ug. 3-hydroxyanthranilic acid/12 ml. final volume in test-
tube.
RESULTS AND DISCUSSION
In Table I is reported the daily excretion of 3-hydroxyanthranilic acid in
normal subjects and in patients with bladder cancer. From the values shown it
appears evident that the subjects with primary carcinoma of the bladder excreted
larger amounts of 3-hydroxyanthranilic acid than the normals.
Table II shows the daily excretion of 3-hydroxyanthranilic acid in the urine
of patients with pelvic and extra-pelvic kidney tumours. It appears that 3-
hydroxyanthranilic acid is always present in the urine of patients with primary
carcinomas of the renal pelvis. Thus 3-hydroxyanthranilic acid appears to be
constantly present in the urines of patients with primary carcinomas of the
urinary tracts. Very recently Benassi, Perissinotto and Allegri (1963) reported
that 3-hydroxyanthranilic acid is excreted in large amounts in the urine of most
of the cases of renal carcinoma they examined. Yet these authors did not find
3-hydroxyanthranilic acid in bladder cancer.
As regards the factors responsible for the increased excretion of 3-hydroxy-
anthranilic acid in the patients with carcinomas of the urinary tracts, we maintain
that it depends essentially upon an alteration of tryptophan-nicotinic acid inter-
relationship. It may be that this increased excretion of 3-hydroxyanthranilic
acid also depends, either upon an increase of ,8-glucuronidase activity (Boyland,
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TABLE I.-Daily Excretion of 3-Hydroxyanthranilic Acid in the Urines of Patients
with Primary Carcinoma of the Bladder (*) and of Normal Subjects (*).
Urine of patients with cancer
Patients 3-hydroxyanthranilic
No. acid mg./24 hr.
lat 1-56
lb 1.58
Ic 1-8
2a 1-05
2b 5-33
3a 2-4
3b Traces
4a 1.01
4b 2-7
5a 6-38
5b 2 76
6a Traces
6b 6- 38
7a 1-5
8a 1-2
8b 0 94
9't 4 0 9ff 4- 34
10' 1-3
lo 1-25
Ila 5-25
12a 5-06
13a Traces
14a 6-0
15a 6-25
16a 18- 37
17a 12 35
18a 15-22
19a 0
19b 0
Urine of normal subjects A-5~~~
Patients 3-hydroxyanthranilic
No. acid mg./24 hr.
1 0
2 0-5
3 Traces
4 0
5 0
6 0
7 0-25
8 Traces
9 0
10 0
11 0
12 0 3
13 Traces
14 0-25
15 0
16 0
17 0
18 Traces
19 0
* Patients were fed a standard hospital diet.
t The urine samples indicated by the same number followed by the letters a, b, c, came from the
same patients but were collected on different days.
I Samples 9', 9" and 10', 10" came from two patients; samples 9' and 10' were collected without
special precautions and were kept at -20° C. ; samples 9" and 10" were collected in ethanol (1: 4 ;
v: v) in order to prevent the enzymic hydrolysis of 3-hydroxyanthranilic acid conjugates. Number
19 refers to a case of prostatic carcinoma with bladder metastasis.
TABLE II.-Daily Excretion of 3-Hydroxyanthranilic Acid in the Urines of Patients
with Kidney Tumours.
3-hydroxyanthranilic
acid; mg./24 hr.
4-72
4-75
7*50
6-70
4-32
5-f62
6-00
1* 63
9 79
Diagnosis
Carcinoma of renal pelvis
Carcinoma of renal pelvis
Carcinoma of renal pelvis
Carcinoma of renal pelvis
Carcinoma of renal pelvis
Papilloma of the pelvis with malignant changes
Malignant hypernephroma
Malignant hypernephroma
Wilms' tumour
Extra-pelvic kidney tumour
Extra-pelvic kidney tumour
Extra-pelvic kidney tumour
Extra-pelvic kidney tumour
Patients
No.
1
2
3
4
5
6
7
8
9
10
11
12
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1958, 1963) or upon an increased rate of tryptophan metabolism via kynurenine.
Anincrease of,?-glucuronidase cannoteasilyexplainthepresence offree 3-hydroxy-
anthranilic acid in the urine of patients with carcinomas of the renal pelvis. If
the second hypothesis were correct, the urines would show an increased excretion
of all the intermediates, especially the last ones of the series (the excretion pro-
ducts of nicotinic acid). Price, Wear, Brown, Satler and Olson (1960) and Price
and Brown (1962) reported the values for excretion of tryptophan metabolites
under normal conditions and after a 2 g. loading dose of tryptophan in normal
controls and in patients with bladder cancer. The excretion of N-mnethyl-2-
pyridone-5-carboxyamide (the main urinary excretion product of nicotinic acid)
was the same in both cases.
SUMMARY
3-Hydroxyanthranilic acid urinary excretion has been studied in normals and
in patients with tumours of the kidney and bladder. In patients with primary
carcinomas ofthe urinary tract the quantity of3-hydroxyanthranilic acid excreted
daily appeared to be greater than in normal controls.
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